Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Nov 28;63(1):55.
doi: 10.1186/s42358-023-00339-7.

Safety and immunogenicity of influenza A(H3N2) component vaccine in juvenile systemic lupus erythematosus

Nadia Emi Aikawa  1   2 , Eduardo Ferreira Borba  3 , Verena Andrade Balbi  4 , Adriana Maluf Elias Sallum  4 , Izabel Mantovani Buscatti  4 , Lucia Maria Arruda Campos  4 , Kátia Tomie Kozu  4 , Cristiana Couto Garcia  5   6 , Artur Silva Vidal Capão  5 , Adriana Coracini Tonacio de Proença  7 , Elaine Pires Leon  3 , Alberto José da Silva Duarte  8 , Marta Heloisa Lopes  7 , Clovis Artur Silva  4   3 , Eloisa Bonfá  3
Affiliations
Clinical Trial

Safety and immunogenicity of influenza A(H3N2) component vaccine in juvenile systemic lupus erythematosus

Nadia Emi Aikawa et al. Adv Rheumatol. .

Abstract

Introduction: Seasonal influenza A (H3N2) virus is an important cause of morbidity and mortality in the last 50 years in population that is greater than the impact of H1N1. Data assessing immunogenicity and safety of this virus component in juvenile systemic lupus erythematosus (JSLE) is lacking in the literature.

Objective: To evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in JSLE.

Methods: 24 consecutive JSLE patients and 29 healthy controls (HC) were vaccinated with influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Influenza A (H3N2) seroprotection (SP), seroconversion (SC), geometric mean titers (GMT), factor increase in GMT (FI-GMT) titers were assessed before and 4 weeks post-vaccination. Disease activity, therapies and adverse events (AE) were also evaluated.

Results: JSLE patients and controls were comparable in current age [14.5 (10.1-18.3) vs. 14 (9-18.4) years, p = 0.448] and female sex [21 (87.5%) vs. 19 (65.5%), p = 0.108]. Before vaccination, JSLE and HC had comparable SP rates [22 (91.7%) vs. 25 (86.2%), p = 0.678] and GMT titers [102.3 (95% CI 75.0-139.4) vs. 109.6 (95% CI 68.2-176.2), p = 0.231]. At D30, JSLE and HC had similar immune response, since no differences were observed in SP [24 (100%) vs. 28 (96.6%), p = 1.000)], SC [4 (16.7%) vs. 9 (31.0%), p = 0.338), GMT [162.3 (132.9-198.3) vs. 208.1 (150.5-287.8), p = 0.143] and factor increase in GMT [1.6 (1.2-2.1) vs. 1.9 (1.4-2.5), p = 0.574]. SLEDAI-2K scores [2 (0-17) vs. 2 (0-17), p = 0.765] and therapies remained stable throughout the study. Further analysis of possible factors influencing vaccine immune response among JSLE patients demonstrated similar GMT between patients with SLEDAI < 4 compared to SLEDAI ≥ 4 (p = 0.713), as well as between patients with and without current use of prednisone (p = 0.420), azathioprine (p = 1.0), mycophenolate mofetil (p = 0.185), and methotrexate (p = 0.095). No serious AE were reported in both groups and most of them were asymptomatic (58.3% vs. 44.8%, p = 0.958). Local and systemic AE were alike in both groups (p > 0.05).

Conclusion: This is the first study that identified adequate immune protection against H3N2-influenza strain with additional vaccine-induced increment of immune response and an adequate safety profile in JSLE. ( www.

Clinicaltrials: gov , NCT03540823).

Keywords: H3N2; Immunogenicity; Influenza; Safety; Systemic lupus erythematosus; Vaccine.

PubMed Disclaimer

References

    1. Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for diagnosis of influenza virus infections in humans. Viruses. 2016;8(4):96. https://doi.org/10.3390/v8040096 . - DOI - PubMed - PMC
    1. Silvennoinen H, Huusko T, Vuorinen T, Heikkinen T. Comparative Burden of influenza A/H1N1, A/H3N2 and B infections in children treated as outpatients. Pediatr Infect Dis J. 2015;34(10):1081–5. https://doi.org/10.1097/INF.0000000000000814 . - DOI - PubMed
    1. Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Koné-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112–22. https://doi.org/10.1016/j.autrev.2011.08.010 . - DOI - PubMed
    1. Heijstek MW, OttdeBruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–12. https://doi.org/10.1136/ard.2011.150193 . - DOI - PubMed
    1. Silva CA, Aikawa NE, Bonfa E. Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol. 2013;9(9):532–43. https://doi.org/10.1038/nrrheum.2013.95 . - DOI - PubMed

Publication types

Associated data